Galectin Therapeutics Reports Q3 GAAP EPS of -$0.04, Exceeding Estimates
Galectin Therapeutics (GALT) reported third-quarter financial results that surpassed analyst expectations, posting a GAAP earnings per share (EPS) of -$0.04, which beat estimates by $0.01. The company demonstrated improved cost management, as research and development expenses saw a significant year-over-year decrease of 40.1%, contributing to a narrowing net loss. The net loss applicable to common stockholders decreased by 56.6% compared to the previous year, totaling $3.6 million. As of September 30, 2026, the company maintained a cash position of $11.7 million. While the balance sheet has been improved through a $105 million debt conversion, the company's future progress remains heavily dependent on its Phase 3 partnership developments.

Tickers: $GALT
Topics: cash position earnings beat net loss reduction r&d expenses